Detail akcie Cytokinetics online

Business Summary: Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Cytokinetics, Inc. revenues decreased 92% to $7.5M. Net loss increased 35% to $526.2M. Revenues reflect Realization of revenue participation rig decrease from $87M to $0K, Revenue Sales of Goods & Serv decrease of 39% to $4M. Higher net loss reflects Research and development increase of 34% to $298M (expense), Stock Based Compensation in R&D increase of 68% to $32.1M (expense).